RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M, Koenig LM, Formisano S, Boehmer DFR, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhöfler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger FS, Rothenfusser S.
Ruzicka M, et al. Among authors: rothenfusser s.
Leukemia. 2020 Apr;34(4):1017-1026. doi: 10.1038/s41375-019-0639-x. Epub 2019 Nov 18.
Leukemia. 2020.
PMID: 31740809
Free PMC article.